|
 |
Why Nimotop®?
Each year, approximately 30,000 Americans suffer a subarachnoid hemorrhage (SAH).1 The highest incidence of disability and death occurs within the first 2 weeks following the initial hemorrhage.2 The leading cause of morbidity and mortality from subarachnoid hemorrhage is cerebral vasospasm.3
Nimotop® provides damage control for SAH.
- Nimotop® reduces the incidence and severity of neurological deficits resulting from vasospasm in patients who have had a recent SAH.4
- Nimotop® is a highly lipophilic calcium channel blocker that effectively crosses the blood brain barrier.
- Nimotop® is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (ie, Hunt and Hess Grades I-V).4
- For patients with Hunt and Hess Grades IV and V, Nimotop® improves the outcome of SAH patients with poor neurological status by improving good recovery while decreasing severe disability and vegetative survival (p=.045)1
- For patients with Hunt and Hess Grades I-III, Nimotop® significantly reduced the risk of cerebral infarction and poor outcome in SAH.5
Sources:
- AHA http://www.americanheart.org/presenter.jhtml?identifier=1192 (Copyright 2005 American Heart Association, Inc.)
- Solomon RA, Fink ME. Current strategies for the management of aneurysmal subarachnoid hemorrhage. Arch Neurol. 1987;44:769-774.
- Kassell NF, Torner JC. The International Cooperative Study on timing of aneurysmal surgery: an update. Stroke. 1984; 15:566-570.
- Nimotop® (nimodipine) Capsules Prescribing Information
December 2005
- Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J. 1989;298:636-642.
|
|
|
|
Clinical Efficacy:
Nimotop has been shown to improve neurological outcome in patients with SAH. Find out more.
Safety:
In patients with SAH, Nimotop® controls damage with a low side
effect profile. Click here.
Pharmacology:
Learn more about the mechanisms of action and pharmacokinetics
associated with Nimotop®. Click here.
Dosage:
When do you begin dosing with Nimotop? How long should patients take
Nimotop? Learn here.
|
|
|
DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY
(See
WARNINGS and DOSAGE AND ADMINISTRATION.) |
| |
- In patients with SAH, Nimotop® controls damage with a low side effect profile.
- Decreased blood pressure is the most common side effect, occurring in 4.4% of patients. Blood pressure should be monitored during therapy.1
- Other side effects occurring at a low frequency of ≥1.0% include headache, nausea, and bradycardia.1
- No clinically significant effects on hematologic factors, renal or hepatic function, or carbohydrate metabolism have been causally associated with oral nimodipine.1
- Nimotop® does not appear to affect anesthetic management.2
|
| |
Sources:
- Nimotop® (nimodipine) Capsules Prescribing
Information December 2005
- Stullken EH, Johnston WE, Prough DS. Implications of nimodipine prophylaxis of cerebral vasospasm on anesthetic management during intracranial aneurysm clipping. J. Neurosurg. 1985; 62:200-205.
|
|
© Bayer HealthCare Pharmaceuticals.
Bayer HealthCare Pharmaceuticals
6 West Belt
Wayne, NJ 07470
The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the US.
|
|
|
